
Twice-daily dosing of the oral JAK inhibitor deuruxolitinib nearly tripled response rates over once-daily dosing in severe alopecia areata.
The American Journal of Managed Care
almost 31 years ago
The Safety and Efficacy of Continuous Heparin Infusion Therapy in the Homealmost 31 years ago
Partial Medication Compliance: The Enigma in Poor Medical Outcomesalmost 31 years ago
The Integration of Case Management and Pharmacy in Managed Care Environmentsalmost 31 years ago
Prevention and Treatment of Osteoporosisalmost 31 years ago
Concentration of Healthcare Costs in Asthma





